1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

Ida E Sonderby, University of Oslo
Dennis van der Meer, University of Oslo
Clara Moreau, Sainte Justine Hospital Research Center
Tobias Kaufmann, University of Oslo
Bragi Walters, deCODE Genetics (Amgen)
Maria Ellegaard, Copenhagen University Hospital
Abdel Abdellaoui, University of Amsterdam
David Ames, University of Melbourne
Katrin Amunts, Research Centre Jülich
Micael Andersson, Umea University

Only first 10 authors above; see publication for full author list.

Journal Title: TRANSLATIONAL PSYCHIATRY
Volume: Volume 11, Number 1
Publisher: SPRINGERNATURE | 2021-03-22, Pages 182-182
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/s41398-021-01213-0
Permanent URL: https://pid.emory.edu/ark:/25593/vxhg6

Final published version: http://dx.doi.org/10.1038/s41398-021-01213-0

Copyright information:
© The Author(s) 2021

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).

Accessed July 4, 2024 12:31 AM EDT
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

Abstract
Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers—the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Introduction
Inter-individual differences in brain structure are highly heritable, but identifying the genes that contribute to brain development is challenging. Genome-wide association studies (GWAS) of brain anatomical structures indicate the influence of many single-nucleotide polymorphisms (SNPs) with small effect sizes, but the links to brain function remain weak. Evidence is emerging that some rare copy number variants (CNVs)—that is, regions of the genome that are either deleted or duplicated—are associated with both substantial brain size and shape differences; for example, the 7q11.23, 22q11.2, 15q11.2, and 16p11.2 proximal and distal CNVs. Many of these CNVs also have a wide-ranging phenotypic impact, including poorer cognitive abilities and increased risk of neurological or neurodevelopmental disorders. The strong impact of these CNVs on brain structure and behaviour make them valuable for studies of the molecular mechanisms contributing to aberrant human neurodevelopment.

The 1q21.1 distal CNV has a known large effect on head circumference, as evident from a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. This, along with its position in a region that is rich in genes unique to the human lineage (i.e. absent in primates), makes the 1q21.1 distal CNV particularly interesting for the study of aberrations in human brain structure. However, its relatively low frequency, 1 in ~3400, (deletions) and 1 in 2100 (duplications), has hampered the study of its effects on brain structure.

1q21.1 distal deletion and duplication carriers are both at higher risk for several neurodevelopmental disorders including schizophrenia, intellectual disability (ID), developmental delay, speech problems, autism spectrum disorders, and more...
disorders, motor impairment\textsuperscript{19,26–28} and epilepsy\textsuperscript{26,29}, in addition to the separate risk for the duplication carriers for ADHD\textsuperscript{30}, bipolar disorder and major depression\textsuperscript{31,32}. Further, general cognitive ability (IQ) was lower in carriers in a small clinical study\textsuperscript{19} and in the UK Biobank\textsuperscript{33}. In addition, 1q21.1 distal CNVs display a positive dose response on head circumference\textsuperscript{19–21}, height and weight\textsuperscript{14,35} and are associated with various somatic diseases and traits, including bone and muscle deviations\textsuperscript{34} and cataract\textsuperscript{36} (deletion only), diabetes\textsuperscript{36} (duplication only) and heart disease\textsuperscript{36–39} (both). Conversely, several studies report carriers without any clinically evident phenotypes\textsuperscript{19,38} and considerable heterogeneity\textsuperscript{20,41}, suggesting incomplete penetrance and variable expressivity. The Df(h1q21)/+ − mouse, deleted in the syntenic 1q21.1 distal region, displays some phenotypes similar to human CNV carriers, including reduced head-to-tail length and altered dopamine transmission in response to psychostimulants, as seen in people with schizophrenia\textsuperscript{42}.

The 1q21 region in humans is rich in low copy number repeats\textsuperscript{20,43} and contains several recurrent CNVs with differing breakpoints\textsuperscript{21,37}. Thus, gene estimates vary, but the core interval encompasses at least 12 protein-coding genes including several human-specific genes such as HYDIN\textsuperscript{21,37}, NOTCH2NL\textsuperscript{22,23} and the DUF1220/Olduvain domain-containing NBPF-encoding genes\textsuperscript{44–46} – the two latter were recently shown to have evolved as a two-gene unit\textsuperscript{47}. Particularly interesting in the context of brain development are the recently characterized NOTCH2NL genes, absent in human’s closest living relatives and shown to prolong cortical neurogenesis\textsuperscript{22,23}.

Despite the strong effects on neurodevelopmental traits and disorders, the impact of the 1q21.1 CNVs on human brain structure is largely unknown. Here, we present the first large-scale systematic neuroimaging study of 1q21.1 distal CNV carriers, investigating brain structure in >37,000 individuals including 28 deletion and 22 duplication carriers. We mapped the effect of the 1q21.1 distal CNV on subcortical volumes, intracranial volume (ICV) and global and regional measures of mean cortical thickness and surface area. We investigated variation in cognitive task performance and supplemented with exploratory mediation analysis of the brain on cognition in the UK Biobank. Given prior findings\textsuperscript{19–21,48}, we explored a dose-dependent effect of copy number on brain structures and decreased cognitive performance for both 1q21.1 distal deletion and duplication carriers in comparison to non-carriers.

Materials and methods

Sample description

The brain structural sample comprises a total of 39 cohorts with genotyping and magnetic resonance imaging (MRI) data—38 from the ENIGMA-CNv consortium in addition to a subsample of the UK Biobank\textsuperscript{49} (project ID #27412). Demographic characteristics for each cohort are described in Supplementary Table 1 with a reference to participants’ collection and datasets including individual inclusion and exclusion parameters. Extended information on diagnosis and family information can be found in Supplementary Note 1 and age distribution of the cohorts in Supplementary Fig. 1. All participants gave written informed consent and sites involved obtained ethical approvals. The main 1q21.1 distal sample consisted of 28 deletion carriers, 22 duplication carriers and 37,088 non-carriers (Table 1) from 13 different datasets and 15 scanner sites with various ascertainment (family, clinical and population studies, case-control study for psychiatric disease) collected up until 30 September 2019. Non-carriers were defined as having no CNVs known to cause neurodevelopmental diseases (as defined in Supplementary Table 2). In the meta-analysis, an independent Icelandic sample from deCODE Genetics consisting of two deletion carriers and five duplication carriers in addition to 1150 non-carriers was added.

Genotyping and QC

The genotypes were obtained by genotyping with commercially available platforms, performed at participating sites for each cohort (Supplementary Table 1). Individuals were excluded exclusively based on quality control (QC) parameters from the CNV calling. No exclusion was done due to ancestry in the primary analysis, but the effect of ancestry was evaluated in a separate analysis (see below).

CNV calls and validation in the core ENIGMA-CNv sample

Almost all cohorts had CNVs called and identified in a unified manner as described previously\textsuperscript{15}. In brief, CNVs were called using PennCNV\textsuperscript{50} and appropriate population frequency (PFB) files and GC (content) model files (Supplementary Table 3 and Supplementary Notes 2 and 3). Samples were filtered and CNVs identified based on standardized QC metrics\textsuperscript{15} (Supplementary Notes 2 and 3). The 1q21.1 distal region was well covered by all arrays (Supplementary Fig. 2). CNVs overlapping the region of interest (1q21.1 distal and 1q21.1 distal and proximal) were identified with the R package iPsychCNV, visualized and manually inspected.

Image acquisition and processing

All brain measures were obtained from structural T1-weighted MRI data collected at participating sites around the world and analysed with the standardized image analysis, FreeSurfer, quality assurance and statistical methods as per the harmonized neuroimaging protocols developed within ENIGMA2\textsuperscript{2} and ENIGMA3 (http://enigma.ini.usc.edu/protocols/imaging-protocols/). Further detail on data
Brain measures were normalized in R v3.3.2 by an inverse normal transformation of the residual of a linear regression on the phenotype correcting for covariates as done previously\textsuperscript{15}. For the primary analysis, covariates were age, age\textsuperscript{2}, sex, scanner site and ICV. In the analysis of ICV, ICV was not included as a covariate. These final covariance-corrected values were used in downstream analysis and are reported for each measure. For comparison between groups, normalization was carried out including only the groups addressed (deletion and non-carriers, duplications and non-carriers) except for the deletion versus duplication comparison, where values from normalization of the entire dataset were used due to the low numbers.

For the copy number dosage effect analysis (i.e. the effect on brain structure of 1q21.1 distal copy number variation), a linear regression on the copy number status of the individuals (deletion = 1, normal = 2, duplication = 3) was performed using the following model: covariance-corrected, 

### Table 1 Demographic data.

|                | ENIGMA-CNV |          |          |          |          | deCODE |          |          |          |
|----------------|------------|----------|----------|----------|----------|--------|----------|----------|----------|
|                | del       | nc       | dup      | P        | del       | nc       | dup      | P        |
| n              | 28        | 37,088   | 22       |          | 2         | 1150     | 5        |          |
| Sex, male (%)  | 15 (54%)  | 17,912 (48%) | 9 (41%) |          | 1 (50%)  | 511 (44%) | 2 (33%) |          |
| Age (mean (SD))| 41.7 (19.0) | 61.1 (12.8) | 55.4 (12.7) <0.001 |          | 53.5 (21.1) | 44.8 (12.4) | 46.4 (16.5) |          |
| Children (age <18 years) | 4 (14%) | 665 (18%) |          | <0.001 | 0         |          | 0        |          |
| Known diagnosis (%) | 11 (39.3%) | 2424 (6.5%) | 7 (32%) | <0.001 | 238 (21%) | 2 (40%) |          |          |
| Disease type (%) |          |          |          |          |          |        |          |          |          |
| ADHD           | 1 (~0%)   |          |          |          | 181 (16%) |          |          |          |
| Autism         | 2 (0.2%)  |          |          |          | 2 (40%)   |          |          |          |
| Bipolar disorder |          |          |          |          | 7 (0.6%)  |          |          |          |
| Clinically recruited (no diagnosis) | 6 (21.4%) | 4 (18%) |          |          |          |        |          |          |
| Dyslexia       | 1 (3.6%)  |          |          |          |          |        |          |          |
| F-ICD-10 diagnosis (UK Biobank) | 858 (2.3%) | 1 (4%) |          |          |          |        |          |          |
| G-ICD10 diagnosis (UK Biobank) | 1 (3.0%) | 1439 (3.8%) | 1 (4%) |          |          |        |          |          |
| MDD            | 1 (~0%)   |          |          |          |          |        |          |          |
| Multiple diagnoses\textsuperscript{a} | 2 (7.2%) | 1 (4.5%) |          |          |          |        |          |          |
| Persistent depressive disorder | 1 (~0%) |          |          |          |          |        |          |          |
| SCZ            | 1 (3.6%)  | 124 (0.3%) |          |          | 48 (4.2%) |          |          |          |
| Scanner sites  | 11        | 15       | 8        |          | 2         | 2       | 1        |          |
| Datasets       | 9         | 13       | 7        |          | 1         | 1       | 1        |          |

\textsuperscript{a}First deletion carrier: agoraphobia, AvPD, OCD, DPD, other substance-related disorder, conduct disorder. Second deletion carrier: specific phobia, social phobia, MDD, AvPD, STPD. Duplication carrier: social phobia, OCD, MDD, AvPD.

\textsuperscript{P}value is based on a \( \chi^2 \) test for categorical values and ANOVA for continuous values.

\textsuperscript{ADHD} attention deficit disorder, clinically recruited in clinical NDD study but without a diagnosis, MDD major depressive disorder, SCZ schizophrenia, del deletion carrier, nc non-carriers, dup duplication carrier, P \( P \) value, AvPD avoidant personality disorder, OCD obsessive-compulsive disorder, DPD dependent personality disorder, STPD schizotypal personality disorder, NS non-significant.

Statistical analysis

Imaging data processing and CNV calling were performed locally and de-identified CNV and imaging data were provided for a central mega-analysis. One of a pair of duplicates was kept. Relatives were removed from the sample used for the main analysis. In addition, we conducted a number of sensitivity analyses to test the robustness of the results (Supplementary Note 5 and Supplementary Tables 5–8). Individuals with a minimum overlap of 0.4 to regions with known pathogenic CNVs (Supplementary Table 2) were excluded from the analysis regardless of copy number status as were individuals from scanner sites without 1q21.1 distal CNV carriers.
normalized brain measure ~ copy number (deletion = 1, non-carrier = 2, duplication = 3). For comparison between groups, a two-sample, two-sided t test assuming equal variance in all carrier/non-carrier groups was employed (R v3.3.2) where deletion or duplication carriers were compared either to each other or to non-carriers. To correct for the multiple comparisons, we calculated the number of independent outcome measures through the spectral decomposition of a correlation matrix using MatSpDlite (https://neurogenetics.qimrberghofer.edu.au/matSpDlite/) of the three global, seven subcortical and 68 regional cortical measures. Based on the ratio of observed eigenvalue variance to its theoretical maximum, the estimated equivalent of independent measures was 36. Thus, we set the significance threshold at $\alpha = 0.05/36 = 0.0014$. We report the uncorrected $P$ values throughout the manuscript.

Effect size is calculated as the absolute effect size (the difference in mean between the two copy number groups in the t test—which, in this case, equals Cohen’s D as the standard deviation of the normalized brain measures is one) and the estimate of beta in the linear regression. Plots were generated using R library ggplot2 v2.2.151. Regional cortical visualization was done with the R package ggsseg v1.5.1.

In a novel analysis, the independent Icelandic data were processed and analysed as the main dataset. We meta-analysed the results using the R package metafor v2.0.0, as previously15.

Cognitive task performance data
We downloaded behavioural performance measures on seven cognitive tests (the pairs matching task, the reaction time task, reasoning and problem-solving tests, the digit span test, the symbol digit substitution test and the trail making A and B tests) from the UK Biobank repository, performed by at least 10% of the participants. The results were processed following the general approach by Kendall et al.16. For more details, see Supplementary Note 6. For the analysis of the seven cognitive measures, we set the significance threshold to $\alpha = 0.05/7 = 0.007$.

Mediation analysis
Mediation analyses were done with the R package mediation v4.4.7. Brain measures were normalized as described above and cognitive tasks were corrected for age, age$^2$ and sex prior to input into the analysis. We report the proportion of the total effect of the CNV on cognitive task performance mediated by the brain measures (‘path ab’/’path c’), with $P$ values calculated through quasi-Bayesian approximation using 5000 simulations. We set the significance threshold at $\alpha = 0.05/((2 + 4) \times 6) = 1.4 \times 10^{-3}$ given the test of two structures for deletion and four for duplication carriers on six cognitive tests. The digit span test was excluded since no 1q21.1 CNV carriers had results from both this cognitive test and brain structural data.

Results
Sample characteristics
The main 1q21.1 distal (146.5–147.4 Mb, hg19) brain structural dataset consisted of 28 deletion and 22 duplication carriers and 37,088 non-carriers (derived from the same scanner sites as the CNV carriers) from ENIGMA-CNv and UK Biobank (Table 1, separate demographics in Supplementary Table 9). The age of CNV carriers was lower (41.7 ± 19.0 (deletions), 55.4 ± 12.7 (duplications), respectively) than that of non-carriers (61.1 ± 12.1) (Table 1). Eleven deletion carriers and seven duplication carriers had a known neurological, neurodevelopmental or psychiatric diagnosis or had been recruited in a clinical CNV study. The remaining carriers either did not have an established diagnosis or were recruited in studies from which diagnostic information was unavailable (Table 1 and Supplementary Table 10). Of the 37,088 non-carriers, 6.5% (2425) had an established neurological, neurodevelopmental or psychiatric disorder.

1q21.1 distal CNV associated with global cortical surface structures
For our main dataset, there was a significant positive association between the number of 1q21.1 distal copies and ICV ($\beta = 1.47, P = 2.8 \times 10^{-25}$) as well as cortical surface area ($\beta = 0.81, P = 1.1 \times 10^{-9}$) (Fig. 1 and Supplementary Table 5) at a significance threshold of $P < 0.0014$ after correction for age, age$^2$, sex, scanner site and ICV. In contrast, a significant negative copy number dosage effect was identified for the caudate ($\beta = -0.49, P = 6.9 \times 10^{-4}$) and hippocampal volumes ($\beta = -0.56, P = 1.3 \times 10^{-4}$). $T$ tests indicated a decrease in ICV (Cohen’s $D = -1.84$ (−17%), $P = 1.6 \times 10^{-22}$) for deletion carriers and an increase for duplication carriers (Cohen’s $D = 0.90$ (+10%), $P = 2.3 \times 10^{-5}$), respectively, compared to non-carriers (Supplementary Table 6). For a raw value plot of ICV, see Supplementary Fig. 3. The cortical surface area dosage effect was primarily driven by the deletion carriers with a significantly lower total cortical surface area (Cohen’s $D = -1.13$ (−23%), $P = 2.1 \times 10^{-9}$) and the dosage effect on caudate and hippocampus was primarily driven by duplication carriers with significantly smaller caudate (Cohen’s $D = -0.71$ (−16%), $P = 0.0012$) and hippocampal (Cohen’s $D = -0.92$ (−15%), $P = 4.1 \times 10^{-5}$) volumes than non-carriers (Fig. 1 and Supplementary Table 7). Adding an independent Icelandic dataset with two deletions, five duplications and 1150 non-carriers (Table 1) in a meta-analysis strengthened the majority of the dosage results (Supplementary Fig. 4 and Supplementary Tables 11 and 12).
and revealed additional significant between-group differences in nucleus accumbens, caudate and putamen (Supplementary Table 12).

A number of sensitivity analyses were run on the main dataset, namely:

(a) Matching each carrier with one non-carrier for age, sex, scanner site and ICV or age, sex, scanner site;
(b) including only: (i) non-affected individuals (i.e. excluding individuals with a known neurodevelopmental or neurological disorder

---

### Fig. 1 Cortical surface area and ICV show a positive dosage effect and caudate and hippocampus a negative dosage effect to copy number in the 1q21.1 distal region in our main sample (ENIGMA-CNV and UK Biobank).

Boxplots of subcortical volumes, cortical surface area and mean cortical thickness and ICV are shown. Deletion carriers (del) in red, non-carriers (nc) in grey and duplication carriers (dup) in blue, respectively. The normalized brain values are presented. Boxplots represent the mean. Copy number dosage effect is noted at the bottom of each panel. Significant differences after correction between groups are noted as *P < 0.0014, **P < 0.00014, ***P = 0.000014. Centre line represents the median, box limits are the upper and lower 25% quartiles, whiskers the 1.5 interquartile range and the points are the outliers. All analyses were corrected for age, age squared, sex, scanner site and ICV (except for ICV).
diagnosis; (ii) adults (age ≥ 18); (iii) non-affected adults; (iv) children (age < 18); (v) ENIGMA-CNV or (vi) UK Biobank; (c) controlling for ancestry; (d) excluding ICV as a covariate or; (e) including first- and second-degree relatives (see Supplementary Note 5 for methods).

These analyses validated the overall effects (Supplementary Tables 5 and 6).

**The 1q21.1 distal CNV is associated with regional brain structures**

The largest dosage effects for the regional cortical surface area were found in the frontal lobes followed by the cingulate cortex—with additional significant effects in three regions of the parietal and temporal lobes (Fig. 2 and Supplementary Table 7). Likewise, through *t*-tests, the largest effects in both deletion and duplication carriers in comparison to non-carriers were observed in the frontal and cingulate cortices (Fig. 2 and Supplementary Table 8).

For regional cortical mean thickness, we identified significant negative dosage effects in the superior temporal region and significant positive dosage effects for the pericalcarine region (Fig. 2 and Supplementary Tables 7 and 8). Similarly, significant increases in mean cortical thickness were observed in deletion carriers versus non-carriers in the pars triangularis and superior temporal regions and a significant decrease in the pericalcarine region (Fig. 2 and Supplementary Table 8). All regional results were corrected for age, age², sex, scanner site and ICV. Sensitivity analyses similar to those performed for subcortical regions confirmed the robustness of the results (Supplementary Tables 7 and 8).

**1q21.1 distal CNV associated with cognitive performance and mediation by brain structures**

Deletion and duplication carriers had different cognitive profiles in comparison to non-carriers when testing for association in seven different neuropsychological tests available from the full UK Biobank sample: deletion carriers had significantly poorer performance in three tests: symbol digit substitution, trail making B and pairs matching, while duplication carriers had significantly poorer performance in two tests: reaction time and the reasoning and problem-solving task (Table 2).

Testing the effect of brain structures on cognitive tests in UK Biobank participants, larger ICV and total surface area were associated with better performance on almost all tests (Table 3 and see Supplementary Table 13 for sample size details). A larger hippocampus was associated with better performance for symbol digit substitution, trail making A and B (Table 3) and a larger caudate was associated with higher performance on the trail making A (Table 3).
Next, we tested whether the brain structures significantly associated with 1q21.1 distal CNV carriers might mediate the effect of the CNV on cognition. For two of the three tests associated with deletion carrier status, there were significant mediation effects (significance threshold $1.4 \times 10^{-3}$): cortical surface area and ICV accounted for 5 and 10%, respectively, of the poorer performance of deletion carriers on symbol digit substitution, and 7 and 17%, respectively, of their poorer performance on the trail making B test (Table 3).

### Discussion

Our main finding was a significant positive dosage effect in humans of 1q21.1 distal copy number on ICV and cortical surface area, with the largest differences in frontal and cingulate cortical surface area. We also identified a significant negative dosage effect on caudate and hippocampal volumes. A number of sensitivity analyses confirmed the robustness of the results. Both 1q21.1 distal deletion and duplication carriers showed poorer cognitive performance, although on different tests, with an indication that decreased ICV/cortical surface area might mediate the effect in deletion carriers.

#### The 1q21.1 distal CNV causes copy dosage effect on brain structures

We found a strong effect of the 1q21.1 distal CNV on the total cortical surface area, while no overall effect on mean cortical thickness was observed. A specific increase in the size of the cortical surface area with little effect on cortical thickness is observed throughout mammalian evolution including the primate lineage leading to humans. This possibly reflects that cortical thickness and surface area appear to be driven by distinct genetic processes. This pattern may be the result of an increased number of symmetric or self-renewing cell-division cycles, leading to an expansion of the neural progenitor pool and subsequently to an increase in the number of cortical neurons—in line with the radial unit hypothesis. Interestingly, although not significant, mean cortical thickness tended to decrease in deletion carriers in frontal cortical surface areas with the highest effect sizes, resembling a pattern found in lissencephaly. This could suggest that large regional decreases in cortical surface area correlate inversely with mean cortical thickness.

The biomechanical forces of brain growth are thought to form the expansion of the cranium so that the skull grows in harmony with the expanding brain. Thus, the positive copy number dosage effect on cortical surface area may directly trigger the effect on head circumference and ICV of 1q21.1 distal carriers due to modifications in pressure. Altered mechanical pressure might also cause the negative copy number dosage effect on the hippocampus and caudate volumes, effects on subcortical volumes also observed in a UK Biobank exploratory study on six individuals with a 1q21.1 distal duplication.

#### Human-specific genes may affect the cortical surface area and cross-species effects

The positive copy number dosage effect on brain structure with the same direction as for weight and height likely results from altered gene expression as observed in 1q21.1 distal CNV cell lines. In an independent experiment on fetal tissue, we also observed dynamic expression patterns of the genes in the 1q21.1 interval consistent with potential roles in cortical neurogenesis and development (Supplementary Note 7 and Supplementary Figs. 5 and 6).

GWAS based on the hg19 genome assembly have not identified hits in the 1q21.1 genomic region for ICV, total cortical or regional surface area. Assembly of the 1q21.1 region and thus gene discovery is complicated due to the presence of numerous low copy number repeats and has been faulty until the GRCh38 genome
This may explain the lack of GWAS hits in the region.

Candidates for a dosage-dependent amplifier of the CNV-associated brain phenotypes are the recently identified human-specific NOTCH2NL genes that confer delayed neuronal differentiation and increased progenitor self-renewal— in line with the radial unit hypothesis.

The areas with the highest regional effect sizes overlap with the areas of the highest expression of NOTCH2NL and C in utero in concordance with an early assembly. This may explain the lack of GWAS hits in the region.

### Table 3: Mediation analysis of brain structures over the association between 1q21.1 distal CNV carrier status and performance in the cognitive tasks in the UK Biobank.

|                      | Deletion | Prop. mediated | P    | Duplication | Prop. mediated | P    |
|----------------------|----------|----------------|------|-------------|----------------|------|
| **Pairs matching**   |          |                |      |             |                |      |
| Caudate              | 0.0023 (0.0053) | 0.66          |      | 3.5E-03     | 0.85           |      |
| Hippocampus          | 0.005 (0.0052)  | 0.34          |      | 9.8E-03     | 0.68           |      |
| SurfArea             | 0.031 (0.0055)  | 1.9E-08       | -0.07 | 0.65        | -4.4E-03       | 0.9  |
| ICV                  | 0.027 (0.0054)  | 4.3E-07       | -0.12 | 0.64        | -0.07          | 0.51 |
| **Reaction time**    |          |                |      |             |                |      |
| Caudate              | -0.0016 (0.0054) | 0.77         |      | -2.3E-03     | 0.67           |      |
| Hippocampus          | 0.01 (0.0053)   | 0.053         |      | 0.01        | 0.04           |      |
| SurfArea             | -0.0095 (0.0056) | 0.091       | 0.02  | 0.13        | 7.3E-04        | 0.78 |
| ICV                  | 0.029 (0.0055)  | 2.4E-07       | -0.1  | 0.07        | -0.03          | 2.4E-03 |
| **Reasoning and problem solving** | | | | | | |
| Caudate              | -0.0059 (0.0091) | 0.51         |      | 5.7E-03     | 0.55           |      |
| Hippocampus          | 0.0031 (0.0089) | 0.73         |      | -9.6E-05     | 0.95           |      |
| SurfArea             | 0.052 (0.0094)  | 2.6E-08       | 0.06  | 0.250       | -7.4E-04       | 0.97 |
| ICV                  | 0.15 (0.0092)   | 3.7E-59       | 0.25  | 0.24        | 0.18           | 0.04 |
| **Symbol digit substitution** | | | | | | |
| Caudate              | 0.0011 (0.0077) | 0.88         |      | -4.2E-03    | 0.83           |      |
| Hippocampus          | 0.04 (0.0075)   | 6.5E-08       |      | -0.01       | 0.82           |      |
| SurfArea             | 0.055 (0.0079)  | 3.8E-12       | 0.05  | 2.4E-03     | 6.9E-04        | 0.99 |
| ICV                  | 0.066 (0.0079)  | 3.6E-17       | 0.1   | 4.0E-04     | 0.13           | 0.68 |
| **Trail making A**   |          |                |      |             |                |      |
| Caudate              | 0.034 (0.0084)  | 5.7E-05       |      | 4.4E-04     | 1              |      |
| Hippocampus          | 0.04 (0.0081)   | 1.0E-06       |      | 3.0E-03     | 0.97           |      |
| SurfArea             | 0.046 (0.0086)  | 1.1E-07       | 0.09  | 0.19        | 1.1E-03        | 0.98 |
| ICV                  | 0.059 (0.0085)  | 6.1E-12       | 0.21  | 0.20        | -0.01          | 0.99 |
| **Trail making B**   |          |                |      |             |                |      |
| Caudate              | 0.021 (0.0083)  | 0.012         |      | -0.01       | 0.79           |      |
| Hippocampus          | 0.04 (0.008)    | 6.9E-07       |      | -0.01       | 0.86           |      |
| SurfArea             | 0.082 (0.0085)  | 6.4E-22       | 0.07  | 8.0E-04     | 8.9E-03        | 0.92 |
| ICV                  | 0.11 (0.0084)   | 1.2E-36       | 0.17  | 1.2E-03     | 0.16           | 0.73 |

Path B is the effect of the brain structure on cognition overall including all 1q21.1 deletion and duplication carriers (4–13 CNV carriers in each group) and non-carriers (n = 10,501–30,924; for exact numbers, see Supplementary Table 13). Each calculation included 5000 simulations.

The significance value for multiple comparisons (1.4 × 10⁻³) are in bold.
developmental effect such as the macrocephaly observed in utero in a 1q21.1 distal duplication carrier\(^{38}\). Our observations of a 2% reduced skull diameter in the 1q21.1 deletion mouse (Supplementary Fig. 7 and Supplementary Notes 8 and 9) and recent findings of decreased total brain volume focused on the temporoparietal and subcortical areas in the deletion mouse\(^{60}\) suggest that genes overlapping between human and mice (nine of ten mice genes are syntenic to the human region\(^{42}\)) and not specific to humans are also involved in the altered skull and brain morphology. However, although diameter and volume are not directly comparable, the 17% decrease in ICV in human 1q21.1 deletion carriers would still point towards a substantial role of human-specific genes or genes with altered functions in comparison to mice. This underlines the need for additional data to disentangle which specific genes are involved in the skull and brain structural phenotypes. Of note, we also observed shorter bones overall in the 1q21.1 deletion mice (Supplementary Fig. 8 and Supplementary Note 9), expanding on previous head-to-tail length data\(^{42}\), and lower bone mineral density in female mice (Supplementary Fig. 9 and Supplementary Note 9), which mirror bone characteristics from human deletion carriers\(^{14}\) increasing the number of observed cross-species effects between the 1q21.1 mice and human 1q21.1 deletion carriers.

**1q21.1 distal CNV deletion and duplication carriers show deficits in different cognitive functions**

Our findings of widespread lower performance across several tests in different domains for both carrier groups in the volunteer-based UK Biobank sample are in line with cognitive results from a recent study\(^{33}\) and support that cognitive function in CNV carriers largely without a neurodevelopmental diagnosis may still be compromised\(^{8,16}\). Interestingly, the frontal and cingulate regions\(^{61}\), with the greatest cortical effect sizes for distal 1q21.1, correlate particularly with cognitive function and have gone through the greatest expansion during human development and evolution\(^{62}\). Our analyses indicated that the decreases in cognitive task performance are partially mediated by the observed differences in ICV and cortical surface area, reflecting the positive correlation between brain volume and intellectual function in line with previous findings\(^{63}\). The decrease in performance for several cognitive tasks in duplication carriers despite a larger ICV and cortical surface area suggests that the positive correlations may only be applicable within a certain narrower range. Interestingly, recent genetic analysis of NOTCH2NL in archaic and modern humans revealed ongoing adaptive evolution towards a lower dosage of the protein\(^{54}\), suggesting negative effects of excessive NOTCH2NL protein.

Our brain structural findings in 1q21.1 distal CNV carriers overlap with brain alterations in associated disorders: for example, ADHD\(^{55}\), autism spectrum disorders\(^{66}\), schizophrenia\(^{67}\), bipolar disorder\(^{68}\), major depressive disorder\(^{69}\) and subtypes of epilepsy\(^{70}\), but the exact overlaps differ between carrier groups. Of note, 1q21.1 distal deletion and duplication carriers display direct, opposite effects on several brain structures, while at risk for the same neurodevelopmental diseases. Other pathogenic CNVs also display overlapping disease risk and similar opposite copy number effects\(^{6,8–15}\) including effects on the cortical surface area in 22q11 and 16p11.2 proximal CNV carriers\(^{6,12–14}\). These CNVs impact different genes, but may converge on the same downstream pathways altering cortical surface area formation, similar to what has been reported for behavioural and neurocognitive phenotypes\(^{55}\).

This also suggests that other risk factors interplay to cause disease. It also supports that subgroups within neurodevelopmental disorders can be defined based on genetic profile and brain structural differences.

We demonstrate large effects of 1q21.1 distal CNVs on brain structure and cognition in humans including a mediation effect. These findings provide insight into molecular mechanisms involved in critical stages of human brain development and mapping of gene dosages to brain structural fingerprints.

**Acknowledgements**

1000BRAINS: The 1000BRAINS study was funded by the Institute of Neuroscience and Medicine, Research Center Juelich, Germany. We thank the Heinz Nixdorf Foundation (Germany) for the generous support of the Heinz Nixdorf Recall Study on which 1000BRAINS is based. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. Funding was also granted by the Initiative and Networking Fund of the Helmholtz Association (Caspers) and the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement 945539 (Human Brain Project SGA3; Amunts, Caspers, Cichon).

Brainscale: The Brainscale study was supported by the Netherlands Organization for Scientific Research (MagnW 480-04-004 (Dorret I. Boomsma), 51.02.060 (Hilleke E. Hulshoff Pol), 668.772 (Dorret I. Boomsma and Hilleke E. Hulshoff Pol), NWO/SPI 56-464-14192 (Dorret I. Boomsma), the European Research Council (ERC-230374) (Dorret I. Boomsma), High Potential Grant Utrecht University (Hilleke E.Hulshoff Pol) and NWO Brain and Cognition 433-09-220 (Hilleke E.Hulshoff Pol).

Betula: The Betula study was funded by the Knut and Alice Wallenberg (KAW) foundation (Hyberg): The Freesurfer segmentations on the Betula sample were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at HPC2N (in Umeå, Sweden), partially funded by the Swedish Research Council through grant agreement no. 2018-05973.

Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative has received support from the participating departments and centres and from external grants; that is, the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland and the Netherlands Organization for Scientific Research (NWO). The research leading to these results also receives funding from the NWO Gravitation grant 'Language in Interaction', the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nos. 602450 (IMAGEMEND), 278948 (TACTICS) and 602805 (Aggrestotype), as well as from the European Community’s Horizon 2020
Osaka: Osaka study was supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS: Grant Number JP18dm0207006), Brain/MINDS& beyond studies (Grant Number JP20dm03072002) and Health and Labour Sciences Research Grants for Comprehensive Research on Persons with Disabilities (Grant Number JP20dk03007081) from the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research (KAKENHI; Grant Numbers JP25293250 and JP16H05375). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan.

PAPF: The PAPF study was supported by Instituto de Salud Carlos III, FIS 0073095, 01/3129, PI020499, PI060507, P1010/183, the SENY Fundació Research Grant CID2005-0308007 and the Fundación Marqués de Valdecilla API07/011. Biological samples from our cohort were stored at the Valdecilla Biobank and genotyping services were conducted at the Spanish ‘Centro Nacional de Genotipado’ (CEGEN-ISClII).

MCG/COBRE: The study is funded by the National Institutes of Health studies R01EB006841, P20GM103472 and P30GM122734 and Department of Energy DE-FF02-99ER66764.

PING: Data collection and sharing for the Paediatric Imaging, Neurocognition and Genetics (PING) Study (National Institutes of Health Grant RC2DA029475) were funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. A full list of PING investigators is at http://pingstudy.ucsd.edu/investigators.html.

QTM: The QTM study was supported by the National Institute of Child Health and Human Development (R01 HD057035) and the National Health and Medical Research Council (NHMRC 486682, 1009064). Australia. Genotyping was supported by NHMRC (389875). Mediland is supported in part by an NHMRC fellowship (APP1103623).

SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grant nos. 01ZZ9603, 01ZZ1003 and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide single-nucleotide polymorphism typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania.

StrokeMRI: StrokeMRI was supported by the Norwegian ExtraFoundation for Health and Rehabilitation(2015/FO5146), the Research Council of Norway (249795, 262372), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073) and the Department of Psychology, University of Oslo.

Sydney MAs: The Sydney Memory and Aging Study (Sydney MAS) is funded by National and HealthMedical Research Council (NHMRC) Programme and Project Grants (ID350833, ID568969 and ID109308). We also thank the Sydney MAS participants and the Research Team.

SYS: The SYS Study is supported by Canadian Institutes of Health Research.

TOP: Centre of Excellence: RCN #23273 and RCN #226971. Part of this work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no. 60020—Scienza Fellows, the Research Council of Norway (RCN) #267097—A lifespan perspective on mental illness: toward precision medicine using multimodal brain imaging and genetics. Ida E. Sønderby and Rune Been are supported by South-Eastern Norway Regional Health Authority (#2020060). Ida E. Sønderby and Ole Andreassen have received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement no. 847776 (CoMaMent project) and the IKG Jebsen Foundation (SKGU-MED-021).

UCLA-UIMCU: The UCLA_UIMCU cohort comprises of six studies which were supported by National Alliance for Research in Schizophrenia and Allied Disorders (NARSAD) (20244 to Prof. Hilleges), the Netherlands Organisation for Health Research and Development (ZonMw) (908-02-123 to Prof. Hulshoff Pol), and Netherlands Organisation for Scientific Research (NWO 9120818 and NWO-VIDI 917-46-370 to Prof. Hulshoff Pol). The GROUP study was funded through the Geestkracht programme of the Dutch Health Research Council (ZonMw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstaZeneca, Eli Lilly and Janssen Cilag) and universities and mental health care organizations (Amsterdams Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ inGeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord-Holland-Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drehtme, Dimend, Met, MGNet Warnseld, Yulis Dordrecht and Parnassia Psycho-medical Center, The Hague. Maistracht: Maastricht University Medical Centre and the mental health institutions: GGZ, GGZ Bredburg, GGZ Oost-Brabant, Vincent van Gogh, for Geestelijke Gezondheid, Mondriaan, Vierenzaag, Zuidergeland GGZ, MET ggz, Universtair Centrum Sint-JozefKortenberg, CAPR University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht, GGZ Centraal and Delta).

UK Biobank: This work made use of data sharing from UK Biobank (under project code 27412).

Others: Work by Pierre Vanderhaeghen was funded by Grants of the European Research Council (ERC Adv Grant GENEVOCORTEX), the EOS Programme, the Belgian FWO, the AXA Research Fund and the Belgian Queen Elizabeth Foundation. Ikuko K. Suzuki was supported by a postdoctoral fellowship of the FRS/FNRS.

Data availability
The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary information files. The data were gathered from various repositories and material requests will need to be placed with individual PIs. I.E.S. can provide additional detail upon correspondence. Data from PING are available at NMH Data Archive: https://ndar.nih.gov/edit_collection.html?id=2607.

Conflict of interest
H.B. is an advisory board member for Nutricia Australia. He has received research funding from the EU ‘Joint Programme Neurodegenerative Disorders’ (JPND) and the National Health and Medical Research Council, Australia. H.J.G. has received travel grants and speakers honoraria from Fresenius Medical Care, Servier, Neuraxpharm and Janssen Cilag. He has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU ‘Joint Programme Neurodegenerative Disorders’ (JPND) and the European Social Fund (ESF). C.R.K.C., P.M.T. and N.I. received partial grant support from Biogen Inc. (Boston), for research unrelated to the topic of this manuscript. B.C.F. has received honoraria from Janssen Cilag, Otsuka and Lundbeck for educational and advisory/consultant activities unrelated with the present research. A.M.D. is a Founder of and holds equity in CorTechs Labs Inc., and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity Inc., and receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. G.B.W., O.G., M.O.U., H.S. and K.S. are employees of deCODE genetics (Amgen). D.P.H. is an employee of Genentech Inc. D.A.A. has received speakers honoraria from Lundbeck, and is a consultant to HealthLytics. A.J.L. has received speaker’s honorarium from Shire. M.J.O., J.H. and v.d.B. report grants from Takeda Pharmaceuticals outside of the submitted work. D.J.S. has received research grants and/or consultancy honoraria from Lundbeck and Sun. D.E.J.L. receives book royalties from Springer Nature and Oxford University Press. T.F. is on the Novo Nordisk advisory board. P.S.S. is on the Expert Advisory Committee of Boigny Australia. All other authors declare no competing financial interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41398-021-01213-0.

Received: 26 November 2020 Revised: 23 December 2020 Accepted: 8 January 2021
Published online: 22 March 2021
Author details
Ida E. Sønderby, Dennis van der Meer, Clara Moreau, Tobias Kaufmann, G. Bragi Walters, Maria Ellegaard, Abdell Elbouda, David Ames, Katrin Amunts, Micael Andersson, Nicola J. Armstrong, Manon Bernard, Nicholas B. Blackburn, John Blangero, Dorret I. Boomsma, Henry Brodaty, Rachel M. Brouwer, Rune Bøen, Wiekke Cahn, Svenja Caspers, Christopher R. K. Ching, Sven Cichon, Simone Ciufolini, Benedetto Crespo-Facorro, Joanne E. Curran, Anders Dale, Shareefa Dalvie, Paola Dazzan, Eco J. C. de Geus, Greig I. de Zubicaray, Sonja M. C. de Zwarte, Sylvane Desrivieres, Joanne L. Doherty, Gary Donohoe, Bogdan Draganiski, Stefan Ehrlich, Else Eiseng, Thomas Espeseth, Kim Fejgin, Simon E. Fisher, Torodd Fladby, Oleksandr Frei, Masaki Fukunaga, Thomas Gareau, Tian Ge, David C. Ghahn, Hans J. Grabe, Nynke A. Groenewold, Emma E. M. Knowles, Kuldeep Kumar, Stephanie Le Hellard, Costin Leu, David E. J. Linden, Jingyu Liu, Arvid Lundervold, Astri Johansen Lundervold, Anne M. Maillard, Nicholas G. Martin, Sandra Martin-Brevet, Karen A. Mather, Samuel R. Mathias, Katie L. McAlmon, Allan F. McRae, Sarah E. Medland, Andreas Meyer-Lindenberg, Torger Moberget, Claudia Modenato, Jennifer Monereio Sanchez, Derek W. Morris, Thomas W. Muhleisen, Robin M. Murray, Jacob Nielsen, Jan E. Nordvik, Lars Nyberg, Loes Olde Loohuis, Roel A. Ophoff, Michael J. Owen, Tomas Paus, Juan M. Peralta, G. Bruce Pike, Carlos Prieto, Erin B. Quinlan, Céline S. Reinfold, Tiago Reis Marques, James H. Rucker, Perminder S. Sachdev, Sigrid B. Sando, Peter R. Schofield, Andrew J. Schork, Gunter Schumann, Jean Shin, Elena Shumskaya, Ana I. Silva, Sanjay M. Sisodiya, Vidar M. Steen, Dan J. Stein, Lachlan T. Strike, Ikouo K. Suzuki, Christian K. Tames, Alexander Teumer, Anupalam Thalamuthu, Diana Tordesillas-Gutierrez, Anne Uhlmann, Magnus O. Ulfarsson, Dennis van ‘t Ent, Marianne B. M. van den Bree, Pierre Vanderhaeghen, Evangelos Vassos, Wei Wen, Katharina Wittfeld.

58. Hofer, E. et al. Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nat. Commun. 11, 4796 (2020).
59. Steinberg, K. M. et al. Single haplotype assembly of the human genome from a hybrid genome. Genome Res. 24, 2066–2076 (2014).
60. Reinwald, J. R. et al. Separable neural mechanisms for the pleiotropic association of copy number variants with neuropsychiatric traits. Transl. Psychiatry 10, 93 (2020).
61. Hill, J. et al. Similar patterns of cortical expansion during human development and evolution. Proc. Natl Acad. Sci. USA 107, 13135 (2010).
62. Fjell, A. M. et al. High-expanding cortical regions in human development and evolution are related to higher intellectual abilities. Cereb. Cortex 25, 36–44 (2015).
63. Deary, I. J., Penke, L. & Johnson, W. The neuroscience of human intelligence differences. Nat. Rev. Neurosci. 11, 201–211 (2010).
64. Lodewijk, G. A., Fernandes, D. P., Vretzakis, I., Savage, J. E. & Jacobs, F. M. J. Evolution of human brain-size associated NOTCH2NL genes proceeds towards reduced protein levels. Mol. Biol. Evol. 37, 2531–2548 (2020).
65. Hoogman, M. et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry 4, 310–319 (2017).
66. van Rooij, D. et al. Cortical and subcortical brain morphometry differences between patients with autism spectrum disorder and healthy individuals across the lifespan: results from the ENIGMA ASD Working Group. Am. J. Psychiatry 175, 359–369 (2018).
67. van Epp, T. G. et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol. Psychiatry 21, 547–553 (2016).
68. Hibar, D. P. et al. Subcortical volumetric abnormalities in bipolar disorder. Mol. Psychiatry 21, 1710–1716 (2016).
69. Schmaal, L. et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol. Psychiatry 21, 806–812 (2016).
70. Whelan, C. D. et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain 141, 391–408 (2018).
for the ENIGMA-CNV working group

Ida E. Sønderby1,2,5, Dennis van der Meer1,4, Clara Moreau1,6,7, G. Bragi Walters8,9, Maria Ellegaard10, Abdel Abdellaoui11,12, David Ames13,14, Katrin Amunts15,16, Micael Andersson17,18, Nicola J. Armstrong19, Manon Bernard20, Nicholas B. Blackburn21, John Blangero21, Dorret I. Boomsma12,22,23, Henry Brodaty24,25, Rachel M. Brouwer26, Robin Bülow21, G. Bruce Pike22,23, Hilleke E. Hulshoff Pol26, Masashi Ikeda27,28, Anne Uhlmann29, Magnus O. Ulfarsson42, Joanne L. Doherty43,44, Gary Donohoe45, Bogdan Draganski1,56,57, Thomas Gareau56, Tian Ge59,60,61, David C. Glahn62,63,64, Neda Jahanshad76, Stephanie Le Hellard90,91, Tobias Kaufmann40, Eco J. C. de Geus12,22,23, Greig I. de Zubicaray41, Sonja M. C. de Zwarte26, Robin Bülow21, G. Bruce Pike22,23, Hilleke E. Hulshoff Pol26, Masashi Ikeda27,28, Anne Uhlmann29, Magnus O. Ulfarsson42, Joanne L. Doherty43,44, Gary Donohoe45, Bogdan Draganski1,56,57, Thomas Gareau56, Tian Ge59,60,61, David C. Glahn62,63,64, Neda Jahanshad76, Stephanie Le Hellard90,91, Tobias Kaufmann40, Eco J. C. de Geus12,22,23, Greig I. de Zubicaray41, Sonja M. C. de Zwarte26, Sylvane Desrivieres42, Joanne L. Doherty43,44, Gary Donohoe45, Bogdan Draganski46,47, Stefan Ehrlich48, Else Eising49, Thomas Espeseth50,51, Kim Fejin52, Simon E. Fisher49,53, Tormod Fladby54,55, Oleksandr Frei49, Hans J. Grabe65,66, Nynke A. Groenewold39, Ömer Güstafsson8, Jan Haavik56,67, Asta K. Haberg69,70, Jeremy Hall43,71, Ryota Hashimoto72,73, Jane Y. Hehir-Kwa74, Derek P. Hibar75, Manon H. J. Hillegers76, Per Hoffmann34,37,77, Laurena Holleran45,78,79,80,81, Georg Homuth81, Jouke-Jan Hottenga42,22,23, Hilleke E. Hulshoff Pol26, Masashi Ikeda27,28, Neda Jahanshed32, Christiane Jockwitz15,31, Stefan Johansson83,84, Erik G. Jönsson85,86, Niklas R. Jörgensen87, Masataka Kikuchi89, Emma E. M. Knowles90, Kuldeep Kumar91,92, Stephanie Le Hellard90,91, Costin Leu11,92,93,94, David E. J. Linden43, Jingyi Liu95, Arvid Lundervold57,95, Astrid Johansen Lundervold96, Anne M. Maillard97, Nicholas G. Martin98, Sandra Martin-Brevet46, Karen A. Mather24,99, Samuel R. Mathias62,64, Katie L. McMahon190, Allan F. McRae1,101,102, Sarah E. Medland103, Andreas Meyer-Lindenberg104, Torgeir Mobergot150, Claudia Modenato16,105, Jennifer Monereo Sánchez106,107, Derek W. Morris108, Thomas W. Mühleisen15,16,13, Robin M. Murray108, Jacob Nielsen52, Jan E. Nordvik109, Lars Nyberg7,11,10, Loes M. Olde Loohuis11, Roel A. Ophoff11,11,12, Michael J. Owen13,14, Tomas Paus113,114, Zdenka Pausova120,114, Juan M. Peralta3,41, G. Bruce Pike115, Carlo Prieto116,17, Céline S. Reinbold33,34,50, Tiago Reis Marques118,119, James J. H. Rucker120, Perminder S. Sachdev121,21, Sigrid B. Sando69,122, Peter R. Schofield123,124, Andrew J. Schork125,126, Gunter Schumann17, Jean Shin127, Elena Shumskaya53,123, Ana I. Silva43,44, Sanjay M. Sisodiya92,94, Vidar M. Steen90,91, Dan J. Stein128, Lachlan T. Strike129,130,131, Ikuo K. Suzuki29,129,130,131, Christian K. Tamnes1,132,133, Alexander Teumer134, Anbupalam Thalatham24, Diana Tordesillas-Gutiérrez36,133, Anne Uhlmann39, Magnus O. Ulfarsson81,136, Dennis van ‘t Ent12,22,
Marianne B. M. van den Bree, Pierre Vanderhaeghen, Evangelos Vassos, Wei Wen, Katharina Wittfeld, Margaret J. Wright, Ingrid Agartz, Srdjan Djurovic, Lars T. Westlye, Hreinn Stefansson, Kari Stefansson, Sébastien Jacquemont, Paul M. Thompson and Ole A. Andreassen.